Multiple Myeloma Coverage from Every Angle

David Siegel, MD, PhD, on Relapsed / Refractory Multiple Myeloma: Final Results From the ASPIRE Trial

Posted: Monday, December 11, 2017

David Siegel, MD, PhD, of the John Theurer Cancer Center at Hackensack University Medical Center, discusses study findings on overall survival of patients treated with carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.